Evogene Analyst Ratings
Evogene Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 213.56% | Alliance Global Partners | → $1.85 | Initiates Coverage On | → Buy |
| 08/18/2023 | 408.47% | Lake Street | $2 → $3 | Maintains | Buy |
| 07/21/2023 | 916.95% | Roth MKM | $1 → $6 | Maintains | Buy |
| 05/02/2023 | 238.98% | Lake Street | → $2 | Initiates Coverage On | → Buy |
| 09/12/2022 | 1255.93% | Aegis Capital | $10 → $8 | Maintains | Buy |
| 09/02/2022 | 408.47% | Roth MKM | $6 → $3 | Maintains | Buy |
| 10/08/2021 | 1086.44% | Roth Capital | → $7 | Initiates Coverage On | → Buy |
| 07/29/2021 | 1594.92% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 12/01/2020 | 1425.42% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/02/2023 | 213.56% | 联盟全球合作伙伴 | →$1.85 | 开始承保 | →购买 |
| 2023年08月18日 | 408.47% | 莱克街 | $2→$3 | 维护 | 买 |
| 07/21/2023 | 916.95% | 罗斯MKM | $1→$6 | 维护 | 买 |
| 05/02/2023 | 238.98% | 莱克街 | →$2 | 开始承保 | →购买 |
| 09/12/2022 | 1255.93% | 宙斯盾资本 | $10→$8 | 维护 | 买 |
| 09/02/2022 | 408.47% | 罗斯MKM | $6→$3 | 维护 | 买 |
| 10/08/2021 | 1086.44% | 罗斯资本 | →$7 | 开始承保 | →购买 |
| 07/29/2021 | 1594.92% | 宙斯盾资本 | →$10 | 开始承保 | →购买 |
| 12/01/2020 | 1425.42% | 康托·菲茨杰拉德 | →$9 | 开始承保 | →超重 |
What is the target price for Evogene (EVGN)?
Evogene(EVGN)的目标价是多少？
The latest price target for Evogene (NASDAQ: EVGN) was reported by Alliance Global Partners on October 2, 2023. The analyst firm set a price target for $1.85 expecting EVGN to rise to within 12 months (a possible 213.56% upside). 4 analyst firms have reported ratings in the last year.
联盟全球合作伙伴于2023年10月2日报道了Evogene(纳斯达克：EVGN)的最新目标价。这家分析公司将目标价定为1.85美元，预计EVGN将在12个月内升至(可能上涨213.56%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Evogene (EVGN)?
Evogene(EVGN)的最新分析师评级是多少？
The latest analyst rating for Evogene (NASDAQ: EVGN) was provided by Alliance Global Partners, and Evogene initiated their buy rating.
联盟全球合作伙伴提供了对Evogene(纳斯达克代码：EVGN)的最新分析师评级，Evogene启动了他们的买入评级。
When is the next analyst rating going to be posted or updated for Evogene (EVGN)?
Evogene(EVGN)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evogene was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Evogene的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Evogene的最后一次评级是在2023年10月2日提交的，所以你应该预计下一次评级将在2024年10月2日左右的某个时候提供。
Is the Analyst Rating Evogene (EVGN) correct?
分析师评级Evogene(EVGN)正确吗？
While ratings are subjective and will change, the latest Evogene (EVGN) rating was a initiated with a price target of $0.00 to $1.85. The current price Evogene (EVGN) is trading at is $0.59, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Evogene(EVGN)评级是以0.00美元至1.85美元的目标价启动的。目前Evogene(EVGN)的交易价格为0.59美元，在分析师的预测范围内。